Skip to main content
. 2008 Nov 4;94(2):678–683. doi: 10.1210/jc.2008-1064

Figure 3.

Figure 3

A, Cotransfection of increasing doses of WT DAX1 (0–50 ng/well) together with WT SF-1 (100 ng/well) shows a dose-dependent activation of the PBX1 promoter. B, By comparing the effects of WT DAX1 alone (50 ng/well, lane 2), WT SF-1 alone (100 ng/well, lane 6), and WT DAX1 (50 ng/well) and WT SF-1 (100 ng/well) together (lane 7), synergistic activation of the PBX1 promoter is seen. This synergistic activation is attenuated when naturally occurring DAX1 mutants associated with severe (R267P, A300P) or mild (I439S) forms of X-linked adrenal hypoplasia are studied (all 50 ng/well). Data represent the mean ± sem of triplicate experiments (unpaired t tests: WT >R267P, A300P; P < 0.01; I439S >R267P, A300P; P < 0.05). RLU, Relative light units.